Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association - 1 May 2017

Deguchi Yasunori, Okabe Hiroshi, Oshima Nobu, Hisamori Shigeo, Minamiguchi Sachiko, Muto Manabu, Sakai Yoshiharu

Abstract excerpt

BACKGROUND: Although trastuzumab improves the outcome of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing gastric or gastroesophageal junction adenocarcinoma (collectively referred to as "gastroesophageal adenocarcinoma"; GEA), no clinical response is observed in a substantial population of patients. A predictive biomarker of trastuzumab response is required. The aim of this study was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Esophageal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Phosphatidylinositol 3-Kinases

Share to PTEN Phosphohydrolase

Share to Receptor, ErbB-2

Share to Trastuzumab

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 27517839
DOI: 10.1007/s10120-016-0627-z

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.PMID 27517839Read ↗

PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.Semantic proximity Read ↗

HER2 expression and PI3K-Akt pathway alterations in gastric cancer.Semantic proximity Read ↗

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.Semantic proximity Read ↗

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with TrastuzumabSemantic proximity Read ↗

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.Semantic proximity Read ↗

Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinomaSemantic proximity Read ↗

Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.Semantic proximity Read ↗

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.Semantic proximity Read ↗

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment responseSemantic proximity Read ↗

Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistanceSemantic proximity Read ↗

Roles of PTEN (Phosphatase and Tensin Homolog) in Gastric Cancer Development and ProgressionSemantic proximity Read ↗

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.